Amgen Inc. (AMGN)

Over the past six months, Amgen's stock price has been influenced by several key events, including a substantial investment to upgrade its manufacturing facility in Juncos, Puerto Rico. Clinical trial results for Repatha demonstrated a significant reduction in major adverse cardiovascular events. Amgen, in partnership with AstraZeneca, received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Tezspire. Amgen reported strong second-quarter earnings, with quarterly revenue climbing 9.4% year-over-year to $9.18 billion. As of October 3, 2025, the share price was $297.89, showing a -4.56% change over the last six months.

Amgen's stock has shown a notable seasonal pattern, historically exhibiting a period of strength from June 30 to September 1, with average returns of +8.58% and a 76% win rate over the last 25 years. This trend is partly attributed to investors moving into defensive healthcare stocks during the summer months.

Amgen Inc. is a leading American multinational biopharmaceutical company headquartered in Thousand Oaks, California, operating within the Pharmaceuticals and Healthcare sector, specifically in the Biotechnology industry. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics targeting serious illnesses across several therapeutic areas, including cancer, heart disease, osteoporosis, inflammatory diseases, rare diseases, nephrology, and neuroscience. Major products include treatments for osteoporosis and bone diseases, autoimmune and inflammatory diseases, cancer, cardiovascular disease, kidney-related diseases, and rare diseases, as well as biosimilars.

Amgen's headquarters are located in Thousand Oaks, California, U.S. The company has a significant global presence, operating in approximately 100 countries and regions worldwide. Amgen maintains manufacturing facilities in the United States, Ireland, the Netherlands, and Singapore. It has extensive sales and marketing networks in the U.S. and Europe and is expanding its commercial operations in regions such as Latin America, Japan, China, and the Middle East.

Amgen has maintained a strong brand reputation in the past year, particularly among patient organizations, being recognized as the number one pharma peer company and ranked third overall in the U.S. by patient organizations. Patient groups awarded the company top marks in critical areas such as integrity, patient centricity, and access to medicines. The acquisition of Horizon Therapeutics likely contributed positively to Amgen's standing, especially among rare disease patient groups.

Institutional investors hold a significant majority of Amgen Inc.'s stock, with ownership percentages ranging from approximately 75% to 82%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. The general public holds around 18% to 28% of the company's stock, while insider ownership is relatively low, typically under 1%.